JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDK) and Aurora kinases that potently inhibits CDK1, CDK2, CDK3, CDK4, CDK6, Aurora-A, and Aurora-B in vitro with 50% inhibition concentration IC50 values of 0.009, 0.004, 0.003, 0.058, 0.253, 0.175, 0.011 and 0.015 μmol/L respectively. JNJ-7706621 selectively inhibits proliferation of both normal human cells and tumor cells of various origins, where the efficacy of JNJ-7706621 is 10-fold greater in tumor cells (IC50 range of 0.112 to 0.514 μmol/L) than normal cells (IC50 range of 3.67 to 5.42 μmol/L). JNJ-7706621 has been found to induce apoptosis, suppress colony formation and inhibit cell growth regardless of p53, retinoblastoma or P-glycoprotein status in human cancer cells.